Your browser doesn't support javascript.
loading
Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
Avenali, Micol; Cerri, Silvia; Ongari, Gerardo; Ghezzi, Cristina; Pacchetti, Claudio; Tassorelli, Cristina; Valente, Enza Maria; Blandini, Fabio.
Afiliação
  • Avenali M; Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy.
  • Cerri S; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
  • Ongari G; Cellular and Molecular Neurobiology Unit, IRCCS Mondino Foundation, Pavia, Italy.
  • Ghezzi C; Cellular and Molecular Neurobiology Unit, IRCCS Mondino Foundation, Pavia, Italy.
  • Pacchetti C; Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • Tassorelli C; Cellular and Molecular Neurobiology Unit, IRCCS Mondino Foundation, Pavia, Italy.
  • Valente EM; Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Pavia, Italy.
  • Blandini F; Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy.
Mov Disord ; 36(5): 1267-1272, 2021 05.
Article em En | MEDLINE | ID: mdl-33617695
ABSTRACT

BACKGROUND:

GBA mutations are the commonest genetic risk factor for Parkinson's disease (PD) and also impact disease progression.

OBJECTIVE:

The objective of this study was to define a biochemical profile that could distinguish GBA-PD from non-mutated PD.

METHODS:

29 GBA-PD, 37 non-mutated PD, and 40 controls were recruited; α-synuclein levels in plasma, exosomes, and peripheral blood mononuclear cells were analyzed, GCase and main GCase-related lysosomal proteins in peripheral blood mononuclear cells were measured.

RESULTS:

Assessment of plasma and exosomal α-synuclein levels did not allow differentiation between GBA-PD and non-mutated PD; conversely, measurements in peripheral blood mononuclear cells clearly distinguished GBA-PD from non-mutated PD, with the former group showing significantly higher α-synuclein levels, lower GCase activity, higher LIMP-2, and lower Saposin C levels.

CONCLUSION:

We propose peripheral blood mononuclear cells as an easily accessible and manageable model to provide a distinctive biochemical profile of GBA-PD, potentially useful for patient stratification or selection in clinical trials. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article